Clinical usefulness of the CSF β-amyloid Aβ1-42/Aβ1-40 ratio for Alzheimer's disease diagnosis: a retrospective study in a Belgian academic hospital

Acta Neurol Belg. 2022 Feb;122(1):245-247. doi: 10.1007/s13760-021-01846-4. Epub 2022 Jan 17.

Authors

Matthieu Deltombe¹, Catherine Fillee¹, Vincent van Pesch²

Affiliations

¹ Department of Clinical Biochemistry, Cliniques Universitaires St-Luc and Université Catholique de Louvain, Brussels, Belgium.
² Department of Neurology, Cliniques Universitaires St-Luc and Université Catholique de Louvain, UClouvain, 10 Avenue Hippocrate, B-1200, Brussels, Belgium. vincent.vanpesch@uclouvain.be.

PMID: 35037226
DOI: 10.1007/s13760-021-01846-4

No abstract available

Keywords: Alzheimer; Aβ1-40; Aβ1-42; Cerebrospinal fluid; Ratio.

Publication types

Letter

MeSH terms

Alzheimer Disease* / cerebrospinal fluid
Alzheimer Disease* / diagnostic imaging
Amyloid beta-Peptides* / cerebrospinal fluid
Belgium
Biomarkers / cerebrospinal fluid
Hospitals
Hospitals, University
Humans
Peptide Fragments* / cerebrospinal fluid
Retrospective Studies

Substances

Amyloid beta-Peptides
Biomarkers
Peptide Fragments
amyloid beta-protein (1-40)
amyloid beta-protein (1-42)